207 related articles for article (PubMed ID: 28898473)
1. Influence of prucalopride on esophageal secondary peristalsis in reflux patients with ineffective motility.
Lei WY; Hung JS; Liu TT; Yi CH; Chen CL
J Gastroenterol Hepatol; 2018 Mar; 33(3):650-655. PubMed ID: 28898473
[TBL] [Abstract][Full Text] [Related]
2. Effects of prucalopride on esophageal secondary peristalsis in humans.
Yi CH; Lei WY; Hung JS; Liu TT; Chen CL
Clin Transl Gastroenterol; 2016 Nov; 7(11):e202. PubMed ID: 27831544
[TBL] [Abstract][Full Text] [Related]
3. Effects of mosapride on secondary peristalsis in patients with ineffective esophageal motility.
Chen CL; Yi CH; Liu TT; Orr WC
Scand J Gastroenterol; 2013 Dec; 48(12):1363-70. PubMed ID: 24099237
[TBL] [Abstract][Full Text] [Related]
4. Effect of prucalopride on sildenafil-induced inhibition of esophageal peristalsis in healthy adults.
Wong MW; Liu TT; Yi CH; Hung JS; Lei WY; Liang SW; Orr WC; Chen CL
J Gastroenterol Hepatol; 2021 Jun; 36(6):1556-1561. PubMed ID: 33080085
[TBL] [Abstract][Full Text] [Related]
5. Effects of mosapride on esophageal secondary peristalsis in humans.
Chen CL; Liu TT; Yi CH; Orr WC
Neurogastroenterol Motil; 2011 Jul; 23(7):606-e249. PubMed ID: 21501334
[TBL] [Abstract][Full Text] [Related]
6. Relevance of ineffective esophageal motility to secondary peristalsis in patients with gastroesophageal reflux disease.
Chen CL; Yi CH; Liu TT
J Gastroenterol Hepatol; 2014 Feb; 29(2):296-300. PubMed ID: 23981079
[TBL] [Abstract][Full Text] [Related]
7. Influence of capsaicin infusion on secondary peristalsis in patients with gastroesophageal reflux disease.
Yi CH; Lei WY; Hung JS; Liu TT; Chen CL; Pace F
World J Gastroenterol; 2016 Dec; 22(45):10045-10052. PubMed ID: 28018112
[TBL] [Abstract][Full Text] [Related]
8. Prucalopride decreases esophageal acid exposure and accelerates gastric emptying in healthy subjects.
Kessing BF; Smout AJ; Bennink RJ; Kraaijpoel N; Oors JM; Bredenoord AJ
Neurogastroenterol Motil; 2014 Aug; 26(8):1079-86. PubMed ID: 24891067
[TBL] [Abstract][Full Text] [Related]
9. Relevance of sleep disturbance to the integrity and characteristics of secondary peristalsis in patients with gastroesophageal reflux disease.
Yi CH; Lei WY; Hung JS; Liu TT; Orr WC; Chen CL
Scand J Gastroenterol; 2017 Feb; 52(2):136-142. PubMed ID: 27608729
[TBL] [Abstract][Full Text] [Related]
10. Impact of ineffective esophageal motility on secondary peristalsis: Studies with high-resolution manometry.
Lei WY; Liu TT; Wang JH; Yi CH; Hung JS; Wong MW; Gyawali CP; Chen CL
Neurogastroenterol Motil; 2021 Apr; 33(4):e14024. PubMed ID: 33174275
[TBL] [Abstract][Full Text] [Related]
11. Effects of esophageal acid infusion vs mosapride on distension-induced secondary peristalsis in humans.
Lei WY; Hung JS; Yi CH; Liu TT; Wong MW; Chen CL
Kaohsiung J Med Sci; 2019 May; 35(5):310-314. PubMed ID: 30897296
[TBL] [Abstract][Full Text] [Related]
12. Differences in the Control of Secondary Peristalsis in the Human Esophagus: Influence of the 5-HT4 Receptor versus the TRPV1 Receptor.
Yi CH; Lei WY; Hung JS; Liu TT; Orr WC; Fabio P; Chen CL
PLoS One; 2016; 11(7):e0159452. PubMed ID: 27438088
[TBL] [Abstract][Full Text] [Related]
13. Intraluminal prucalopride increases propulsive motor activities via luminal 5-HT
Shokrollahi M; Chen JH; Huizinga JD
Neurogastroenterol Motil; 2019 Oct; 31(10):e13598. PubMed ID: 31012538
[TBL] [Abstract][Full Text] [Related]
14. Prucalopride induces high-amplitude propagating contractions in the colon of patients with chronic constipation: a randomized study.
Miner PB; Camilleri M; Burton D; Achenbach H; Wan H; Dragone J; Mellgard B
Neurogastroenterol Motil; 2016 Sep; 28(9):1341-8. PubMed ID: 27270968
[TBL] [Abstract][Full Text] [Related]
15. Effects of lidocaine on esophageal secondary peristalsis in humans.
Chen CL; Liu TT; Yi CH
Neurogastroenterol Motil; 2010 Jun; 22(6):606-10. PubMed ID: 20337946
[TBL] [Abstract][Full Text] [Related]
16. Effects of esophageal capsaicin instillation on acid induced excitation of secondary peristalsis in humans.
Liu TT; Yi CH; Lei WY; Hung JS; Chen CL; Orr WC
J Gastroenterol Hepatol; 2016 Feb; 31(2):364-9. PubMed ID: 26250995
[TBL] [Abstract][Full Text] [Related]
17. Differences in esophageal corpus motility in patients with pathological and non-pathological gastroesophageal reflux.
Klopocka M; Budzyński J; Swiatkowski M; Pulkowski G; Meder A
Med Sci Monit; 2006 Sep; 12(9):CR387-92. PubMed ID: 16940933
[TBL] [Abstract][Full Text] [Related]
18. Ineffective esophageal motility is a primary motility disorder in gastroesophageal reflux disease.
Ho SC; Chang CS; Wu CY; Chen GH
Dig Dis Sci; 2002 Mar; 47(3):652-6. PubMed ID: 11911355
[TBL] [Abstract][Full Text] [Related]
19. Control of esophageal distension-induced secondary peristalsis by the GABA(B) agonist baclofen in humans.
Chen CL; Liu TT; Yi CH
Neurogastroenterol Motil; 2011 Jul; 23(7):612-e250. PubMed ID: 21501336
[TBL] [Abstract][Full Text] [Related]
20. Gamma-aminobutyric acid receptor type B agonist baclofen inhibits acid-induced excitation of secondary peristalsis but not heartburn sensation.
Wong MW; Hung JS; Liu TT; Yi CH; Lei WY; Chen CL
J Gastroenterol Hepatol; 2019 Feb; 34(2):370-375. PubMed ID: 30069912
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
